scholarly article | Q13442814 |
P819 | ADS bibcode | 1994PNAS...9110722Z |
P356 | DOI | 10.1073/PNAS.91.22.10722 |
P932 | PMC publication ID | 45094 |
P698 | PubMed publication ID | 7938018 |
P5875 | ResearchGate publication ID | 15261255 |
P2093 | author name string | Cohen O | |
Wetzler M | |||
Ben-Yehuda D | |||
Avraham A | |||
Ben-Neriah Y | |||
Melloul D | |||
Zion M | |||
P2860 | cites work | The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia | Q24613429 |
Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia | Q28265670 | ||
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene | Q28287743 | ||
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene | Q28512170 | ||
Role for DNA methylation in genomic imprinting | Q29618669 | ||
Hypomethylation distinguishes genes of some human cancers from their normal counterparts | Q29619217 | ||
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival | Q33457480 | ||
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl | Q33559187 | ||
Transforming genes in chronic myelogenous leukemia | Q33560907 | ||
Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia | Q34302000 | ||
Use of restriction enzymes to detect potential gene sequences in mammalian DNA. | Q35079757 | ||
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia | Q35595317 | ||
Differential expression of type-specific c-abl mRNAs in mouse tissues and cell lines | Q36847864 | ||
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562 | Q37344872 | ||
Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia | Q37511866 | ||
Recurring chromosome abnormalities in leukemia and lymphoma | Q37929357 | ||
High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. | Q38339731 | ||
Therapeutic options in chronic myeloid leukaemia | Q38617810 | ||
Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene | Q40562591 | ||
DNA methylation and genomic imprinting | Q40754526 | ||
The nuclear tyrosine kinase c-Abl negatively regulates cell growth | Q42799874 | ||
Parental origin of chromosomes involved in the translocation t(9;22). | Q43592920 | ||
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene | Q43900370 | ||
Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. | Q48125063 | ||
Alternative 5' exons in c-abl mRNA. | Q48368062 | ||
Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cells | Q48393003 | ||
Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia. | Q51658122 | ||
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia | Q59064021 | ||
Imprints on islands | Q64441632 | ||
Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis. | Q64974705 | ||
Studies of BCR and ABL gene rearrangements in chronic myelogenous leukemia patients by conventional and pulsed-field gel electrophoresis using gel inserts | Q69540304 | ||
Methylation of the Hprt gene on the inactive X occurs after chromosome inactivation | Q69687603 | ||
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia | Q69944833 | ||
Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia | Q70167698 | ||
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations | Q70220517 | ||
Lack of imprinting of BCR | Q72017447 | ||
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML | Q72078669 | ||
P433 | issue | 22 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
DNA methylation | Q874745 | ||
P304 | page(s) | 10722-10726 | |
P577 | publication date | 1994-10-01 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia | |
P478 | volume | 91 |
Q73916772 | ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL |
Q33961765 | Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia |
Q36573030 | Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning |
Q35058707 | Advanced-phase chronic myeloid leukemia |
Q41167757 | Are ABL and BCR imprinted? |
Q35184329 | Chronic myelogenous leukemia: a review and update of therapeutic strategies |
Q34765301 | Chronic myelogenous leukemia: mechanisms underlying disease progression. |
Q38193659 | Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy |
Q38344869 | Control of methylation spreading in synthetic DNA sequences by the murine DNA methyltransferase |
Q41730013 | DNA methylation as a target for drug design |
Q34792998 | DNA methylation changes in leukaemia |
Q37873228 | DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. |
Q36986433 | DNA methylation: its role in cancer development and therapy |
Q41592450 | DNA methylation: regulation of gene expression and role in the immune system |
Q41723122 | DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines |
Q38941081 | DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia |
Q33806626 | Differential methylation of genes associated with cell adhesion in preeclamptic placentas. |
Q24810666 | Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region |
Q36429559 | Epigenetic therapy with decitabine for myelodysplasia and leukemia |
Q42816880 | Heritable gene repression through the action of a directed DNA methyltransferase at a chromosomal locus |
Q33536277 | High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene |
Q43658865 | Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction |
Q40305071 | Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia |
Q35828742 | Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia |
Q39520549 | Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele |
Q36142412 | Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients. |
Q35571293 | Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. |
Q80586970 | Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts |
Q34278271 | Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia |
Q39808706 | Methylation of CpG dinucleotides in the open reading frame of a testicular germ cell-specific intronless gene, Tact1/Actl7b, represses its expression in somatic cells |
Q54266084 | Methylation status of CEBPA gene promoter in chronic myeloid leukemia. |
Q38289376 | Methylation-associated Transcriptional Silencing of the Major Histocompatibility Complex-linked hsp70 Genes in Mouse Cell Lines |
Q34176567 | NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia |
Q36851400 | Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases |
Q35728742 | Novel therapies for patients with chronic myeloid leukemia |
Q54839818 | Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. |
Q73934848 | Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region |
Q35571288 | Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg |
Q38327560 | RETRACTED: Alteration of p73 in acute myelogenous leukemia |
Q33959680 | Roles of cell division and gene transcription in the methylation of CpG islands. |
Q34053843 | Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas |
Q33543982 | The DNA methylation paradox |
Q36822880 | Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). |
Q41607022 | p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia |